Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2024 Financial Results on November 12, 2024
Rhea-AI Summary
Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company, has announced that it will report its third quarter fiscal year 2024 financial results after the market closes on Tuesday, November 12th, 2024. The company will host a conference call at 5:00 p.m. Eastern Time on the same day to discuss the quarterly results and provide a corporate update, followed by a question and answer session.
Interested parties can access the live webcast through the company's website at investors.organogenesis.com or via a provided link. A teleconference option is also available. The webcast will be archived on the company's website for approximately one year after the event.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, ORGO gained 1.56%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
CANTON, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that third quarter of fiscal year 2024 financial results will be reported after the market closes on Tuesday, November 12th.
Management will host a conference call at 5:00 p.m. Eastern Time on November 12th to discuss the results of the quarter and provide a corporate update with a question and answer session. Those who would like to participate may access the live webcast here, or access the teleconference here. The live webcast can also be accessed via the company’s website at investors.organogenesis.com. The webcast will be archived on the company website for approximately one year.
About Organogenesis Holdings Inc.
Organogenesis Holdings Inc. is a leading regenerative medicine company focused on the development, manufacture, and commercialization of solutions for the advanced wound care and surgical and sports medicine markets. Organogenesis offers a comprehensive portfolio of innovative regenerative products to address patient needs across the continuum of care.
FAQ
When will Organogenesis Holdings (ORGO) report its Q3 2024 financial results?
What time is the Organogenesis Holdings (ORGO) Q3 2024 earnings call scheduled for?
How can investors access Organogenesis Holdings' (ORGO) Q3 2024 earnings call?
How long will the webcast of Organogenesis Holdings' (ORGO) Q3 2024 earnings call be available?
